EWA
NMRA icon

EverSource Wealth Advisors’s Neumora Therapeutics NMRA Stock Holding History

EverSource Wealth Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-298
Closed -$582 – 4506
2026
Q1 		$582 Sell
298
-21
-7% -$54 ﹤0.01% 4026
2025
Q4 		$571 Sell
319
-17
-5% -$37 ﹤0.01% 3846
2025
Q3 		$612 Sell
336
-801
-70% -$1.29K ﹤0.01% 3901
2025
Q2 		$834 Buy
1,137
+1,042
+1,097% +$789 ﹤0.01% 3777
2025
Q1 		$95 Buy
95
+92
+3,067% +$158 ﹤0.01% 3838
2024
Q4 		$32 Buy
+3
New +$36 ﹤0.01% 3679

Other funds holding NMRA

WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
AH
Addis & Hill Wayne, Pennsylvania $181M AUM 21.74% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

EverSource Wealth Advisors's NMRA Position: Q2 2026 in Review

EverSource Wealth Advisors sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 298 shares — an estimated $582 sold.

EverSource Wealth Advisors first reported a position in NMRA in Q4 2024 and held it in 6 quarters. The position peaked at $834 in Q2 2025. 14 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • EverSource Wealth Advisors reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EverSource Wealth Advisors sold 298 Neumora Therapeutics shares in Q2 2026, an estimated $582.
  • EverSource Wealth Advisors first reported a position in Neumora Therapeutics in Q4 2024 and held it in 6 quarters.
  • EverSource Wealth Advisors's Neumora Therapeutics position peaked at $834 in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.